Group 1 - Huaneng Power announced that its shareholder Hunan Energy Group plans to reduce its stake by up to 20.31 million shares, not exceeding 1% of the total share capital [1] - Ankai Bus reported a production of 1,012 buses in August, a year-on-year increase of 68.06%, with sales of 773 buses, up 46.95% year-on-year [1] - Lianhuan Pharmaceutical received a drug registration certificate for Famotidine injection, classified as a Class 3 chemical drug [1][2] Group 2 - Dongrui Co. reported sales of 94,800 pigs in August, generating revenue of 160 million yuan, a month-on-month decrease of 5.48% [3] - Tiancheng Control's subsidiary received a notification for a passenger car seat assembly project, expected to start production in April 2026 [5] - ST Huluwa obtained a drug registration certificate for Cefodizime capsules, a third-generation broad-spectrum cephalosporin [6] Group 3 - Jiulong Biotech announced the resignation of its Vice Chairman and General Manager Liang Hongjun due to work adjustments [8] - Guanhua High-tech's shareholder plans to reduce its stake by up to 17.50 million shares, not exceeding 1% of the total share capital [9] - Hebei Steel received approval to issue bonds totaling up to 10 billion yuan [10] Group 4 - Yunnan Energy Investment's subsidiaries received a total of 309 million yuan in renewable energy price subsidies [12] - Zhenghong Technology reported sales of 16,800 pigs in August, with a revenue of 22.87 million yuan, showing a year-on-year increase in sales volume of 63.31% [14] - Jilin Aodong's subsidiary received a drug registration certificate for a solution used in asthma treatment [16] Group 5 - Aonong Biological reported a 26.84% year-on-year increase in pig sales volume in August, reaching 150,100 pigs [18] - Xingdesheng announced a share repurchase plan with a budget of 15 to 30 million yuan [20] - Yueyang Lin Paper's Chairman Ye Meng resigned due to work adjustments [22] Group 6 - Kangchen Pharmaceutical's controlling shareholder plans to reduce its stake by up to 4.78 million shares, not exceeding 3% of the total share capital [23] - Changchun Yidong's General Manager Liu Xiaodong resigned due to work adjustments [25] - Zhongzai Resources' subsidiary received a government subsidy of 12.75 million yuan [26] Group 7 - Tianyu Biological reported a 41.89% month-on-month increase in sales revenue from pig sales in August [27] - Changfei Optical's shareholder Draka Comteq B.V. reduced its stake from 10% to 5% [27] - Zhongchuan Technology's Chairman Wu Xingwang resigned due to work adjustments [28] Group 8 - Huakang Clean announced a successful bid for a medical service construction project valued at 131 million yuan [29] - Yuegui Co. plans to establish a wholly-owned subsidiary with a registered capital of 100 million yuan [31] - Baisheng Intelligent's Vice General Manager and Board Secretary Huang Lijun resigned for personal reasons [32] Group 9 - Jiangsu Shuntian will change its stock name to "Suhao Fashion" starting September 10, 2025 [34] - Jiahe Meikang's shareholder plans to reduce its stake by up to 1.3759 million shares, not exceeding 1% of the total share capital [35] - Heng Rui Pharmaceutical received approval for clinical trials of HRS-4729 injection [37] Group 10 - Changfei Optical's shareholder plans to reduce its stake by up to 110,000 shares, not exceeding 0.15% of the total share capital [39] - Yutong Bus reported sales of 4,260 vehicles in August, a year-on-year increase of 16.78% [40] - JinkoSolar received 646 million yuan in renewable energy subsidies in August, a 248% increase year-on-year [41] Group 11 - Beijing Lier signed a strategic cooperation agreement with SenseTime and Xiwang Technology for AI collaboration [43] - Gongdong Medical's controlling shareholder plans to reduce its stake by up to 3% [44] - Zhonghuan Hailu terminated its control change plan and resumed trading [46] Group 12 - Longzi Co. reported a tax payment of 22.27 million yuan due to a tax audit [48] - Guoguang Chain's controlling shareholder plans to reduce its stake by up to 2.99% [49] - Guoxin Technology successfully tested a new high-performance chip for automotive electronics [50] Group 13 - GF Securities reported a cumulative increase in borrowings exceeding 20% of its net assets [51] - China Construction Bank's subsidiary plans to increase capital by 3 billion yuan [52] - Jifeng Technology plans to establish a wholly-owned subsidiary with a capital of 50 million yuan [53] Group 14 - Jiantou Energy received approval for a stock issuance plan to specific investors [54] - Shanghai Laishi's executives plan to collectively increase their holdings by at least 6 million yuan [55] - Wencan Co. reported a fire incident at its subsidiary, with no casualties reported [56]

Group 1 - Jilin Aodong Pharmaceutical Group's subsidiary received a drug registration certificate for "Sulfuric Terbutaline Nebulized Inhalation Solution" from the National Medical Products Administration [1] - As of January to June 2025, Jilin Aodong's revenue composition is as follows: 73.63% from the pharmaceutical industry, 16.59% from wholesale and retail of chain pharmacies, 7.39% from food, 1.76% from other industries, and 0.62% from other businesses [1] - Jilin Aodong's market capitalization is currently 23 billion yuan [1]

Group 1 - The company Jilin Aodong (000623.SZ) announced that its subsidiary, Jilin Aodong Pharmaceutical Group Yanji Co., Ltd., received a drug registration certificate from the National Medical Products Administration for "Sulfate Terbutaline Nebulization Solution" [1] - The indication for the sulfate terbutaline nebulization solution is to relieve bronchial asthma, chronic bronchitis, emphysema, and other pulmonary diseases associated with bronchospasm [1]

Core Viewpoint - Jilin Aodong Pharmaceutical Group Co., Ltd. has received a drug registration certificate from the National Medical Products Administration for "Sulfate Terbutaline Nebulized Inhalation Solution," indicating a significant development in its product portfolio [1]. Group 1 - The newly approved product is indicated for the relief of bronchial asthma, chronic bronchitis, emphysema, and other pulmonary diseases associated with bronchospasm [1].

Core Viewpoint - Jilin Aodong announced that its subsidiary Yanji Pharmaceutical has received a drug registration certificate from the National Medical Products Administration for "Sulfuric Terbutaline Nebulized Inhalation Solution," which is used to relieve bronchial asthma, chronic bronchitis, emphysema, and other lung diseases associated with bronchospasm [1] Group 1 - The drug registration certificate enhances the company's product structure [1] - The approval enriches the variety of products offered by the company [1] - This development strengthens the company's core competitiveness in the pharmaceutical industry [1]

Core Viewpoint - Jilin Aodong announced that its subsidiary Yanji Pharmaceutical has received the "Drug Registration Certificate" for "Sulfate Terbutaline Nebulized Inhalation Solution" from the National Medical Products Administration, which is used to relieve bronchial asthma, chronic bronchitis, emphysema, and other lung diseases associated with bronchospasm [1] Group 1 - The approval of the drug registration certificate enhances the company's product structure [1] - The new product enriches the variety of the company's offerings [1] - This development strengthens the company's core competitiveness [1]

Core Viewpoint - Jilin Aodong (000623.SZ) announced that its subsidiary, Jilin Aodong Pharmaceutical Group Yanji Co., Ltd. (referred to as "Yanji Pharmaceutical"), has received the "Drug Registration Certificate" for "Sulbutamol Sulfate Nebulized Inhalation Solution" from the National Medical Products Administration [1] Group 1 - The indication for Sulbutamol Sulfate Nebulized Inhalation Solution is to relieve bronchial asthma, chronic bronchitis, emphysema, and other pulmonary diseases associated with bronchospasm [1]

Core Viewpoint - Jilin Aodong Pharmaceutical Group's subsidiary has received a drug registration certificate for "Salbutamol Sulfate Nebulization Solution" from the National Medical Products Administration, indicating a significant development in the company's product offerings [1] Company Summary - Jilin Aodong Pharmaceutical Group's subsidiary, Jilin Aodong Pharmaceutical Group Yanji Co., Ltd., has been granted a registration certificate for a new medication [1] - The newly approved medication is indicated for the relief of bronchial asthma, chronic bronchitis, emphysema, and other lung diseases associated with bronchospasm [1]

证券代码:000623 证券简称:吉林敖东 公告编号:2025-049 吉林敖东药业集团股份有限公司 关于控股子公司获得药品注册证书的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，吉林敖东药业集团股份有限公司（以下简称"公司"）控股子公司吉 林敖东药业集团延吉股份有限公司（以下简称"延吉药业"）收到国家药品监督 管理局下发的"硫酸特布他林雾化吸入用溶液"的《药品注册证书》。现就相关 情况公告如下： 一、《药品注册证书》的主要内容 1.硫酸特布他林雾化吸入用溶液 药品通用名称：硫酸特布他林雾化吸入用溶液 英文名/拉丁名：Terbutaline Sulfate Nebuliser Solution 主要成份：硫酸特布他林 剂型：吸入制剂 规格：2ml：5mg 注册分类：化学药品4类 药品注册标准编号：YBH21102025 药品有效期：24个月 包装规格：5支/袋，4袋/盒 处方药/非处方药：处方药 受理号：CYHS2401108 证书编号：2025S02676 上市许可持有人名称：吉林敖东药业集团延吉股份有限公司 上市许可持有人地址： ...

Core Viewpoint - Jilin Aodong has evolved into a holding group company driven by both the pharmaceutical industry and financial capital, aiming to rejuvenate traditional Chinese medicine in modern society through innovation [6][13]. Company Development - Founded in 1957, Jilin Aodong has undergone significant transformations, including the establishment of a pharmaceutical factory in 1981, a shareholding reform in 1993, and its listing on the Shenzhen Stock Exchange in 1996 [6]. - The company has developed a comprehensive industrial chain in the pharmaceutical sector, integrating cultivation, research, production, testing, and sales [7]. Product Innovation - Jilin Aodong's core product, "Anshen Bnuna Liquid," has been a market leader for over 40 years, with a market share of 60% to 70% in its category, generating over 700 million yuan in annual sales [7]. - The company has a diverse product portfolio with 628 drug approval numbers, including 47 exclusive varieties, and has completed the listing of 525 traditional Chinese medicine formula granules [9]. Technological Advancements - The company has invested 1 billion yuan in an automated production line for traditional Chinese medicine extraction, set to be operational by the end of 2024, with an annual extraction capacity of 5,000 tons [10]. - The production process has transitioned to a fully automated system, enhancing efficiency and precision in drug manufacturing [10]. Market Expansion - Jilin Aodong is expanding into the health industry, producing over 200 health products, with some individual products generating over 1 million yuan in annual sales [11]. - The company is also investing in financial sectors, with a reported investment income of 1.206 billion yuan in the first half of 2025, a 53.67% increase year-on-year [12]. Financial Performance - In the first half of 2025, Jilin Aodong achieved a net profit of 1.282 billion yuan, a significant increase of 138.44% compared to the previous year [12]. - The company's total assets reached 34.151 billion yuan, with a debt-to-asset ratio of 11.54%, indicating a strong financial position [12]. Social Responsibility - Jilin Aodong has distributed 4.505 billion yuan in cash dividends over 17 years and has contributed to local economic development through agricultural projects, generating 7.76 billion yuan in output value over the past decade [12].